To bring next-generation immunotherapies for multiple myeloma and B cell disorders to market that will transform outcomes by prolonging survival while preserving quality of life for patients worldwide.
To redefine the standard of care, establishing a new treatment paradigm for haematological cancers and B cell disorders.
We are committed to delivering meaningful outcomes that matter to patients.
We advance science that improves and extends lives, guided by intellectual and scientific curiosity.
We uphold the highest ethical standards in everything we do, staying genuine in our intent to serve patients.
We relentlessly pursue high-impact, data-driven therapies.
Driven by a shared vision, we foster team solidarity and build global partnerships to accelerate progress.
On the basis of outstanding clinical results, we strive to generate robust, sustainable returns for investors.
HaemaLogiX is the only biotechnology company in the world developing therapies against the Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA). These antigens are expressed on the surface of malignant plasma cells in multiple myeloma but are absent from healthy plasma cells, allowing HaemaLogiX's therapies to selectively destroy cancer cells while sparing normal immune function — a sharp contrast to existing treatments that deplete all plasma cells.
HaemaLogiX's scientific team identified KMA and LMA as accessible cancer-specific targets and built the foundational intellectual property around them. The KappaMab™ antibody, the KMCAR™ T-cell therapy, and a pipeline of bispecific and trispecific antibodies are all built on this proprietary target biology. The company holds 84 patent filings across 10 patent families covering composition, method-of-use, and manufacturing across major jurisdictions.
Most current myeloma immunotherapies — including anti-CD38 antibodies, anti-BCMA agents, and BCMA-directed CAR-T therapies — target antigens that are present on both malignant and healthy plasma cells. HaemaLogiX's KappaMab™ and KMCAR™ therapies target the Kappa Myeloma Antigen, which is found on malignant plasma cells but not on healthy ones. This selective targeting is the core scientific differentiator of HaemaLogiX's approach and the foundation of its clinical development program.